CIK 0001953926 · <br>Emerging growth company
Zenas BioPharma, Inc.
Sign in to watch- Ticker
- ZBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857-271-2954
- Business address
- 852 WINTER STREET, SUITE 250, WALTHAM, MA, 02451
- Former names
- Zenas BioPharma (Cayman) Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-16 | Fairmount Funds Management LLC Director | Conversion · Series B Convertible Preferred Stock | −6,163,236 | 0 | ||
| 2024-09-16 | Fairmount Funds Management LLC Director | Conversion · Series C Convertible Preferred Stock | −2,614,287 | 0 | ||
| 2024-09-16 | MOULDER LEON O JR Chief Executive Officer | Conversion | +164,523 | 1,280,022 | ||
| 2024-09-16 | MOULDER LEON O JR Chief Executive Officer | Conversion | +108,381 | 112,901 | ||
| 2024-09-16 | MOULDER LEON O JR Chief Executive Officer | Conversion | +372,017 | 1,652,039 | ||
| 2024-09-16 | MOULDER LEON O JR Chief Executive Officer | Conversion | +48,254 | 161,155 | ||
| 2024-09-16 | MOULDER LEON O JR Chief Executive Officer | Conversion · Series Seed Convertible Preferred Stock | −1,428,571 | 0 | ||
| 2024-09-16 | MOULDER LEON O JR Chief Executive Officer | Conversion · Series A Convertible Preferred Stock | −941,088 | 0 | ||
| 2024-09-16 | MOULDER LEON O JR Chief Executive Officer | Conversion · Series B Convertible Preferred Stock | −3,230,268 | 0 | ||
| 2024-09-16 | MOULDER LEON O JR Chief Executive Officer | Conversion · Series B Convertible Preferred Stock | −418,996 | 0 | ||
| 2024-09-16 | ENRIGHT PATRICK G Director | Conversion | +723,812 | 723,812 | ||
| 2024-09-16 | ENRIGHT PATRICK G Director | Conversion | +1,003,592 | 1,727,404 | ||
| 2024-09-16 | ENRIGHT PATRICK G Director | Conversion | +334,530 | 334,530 | ||
| 2024-09-16 | ENRIGHT PATRICK G Director | Purchase | +440,000 | $17.00 | $7.5M | 774,530 |
| 2024-09-16 | ENRIGHT PATRICK G Director | Conversion · Series B Convertible Preferred Stock | −6,284,933 | 0 | ||
| 2024-09-16 | ENRIGHT PATRICK G Director | Conversion · Series C Convertible Preferred Stock | −8,714,293 | 0 | ||
| 2024-09-16 | ENRIGHT PATRICK G Director | Conversion · Series C Convertible Preferred Stock | −2,904,764 | 0 | ||
| 2024-09-16 | Fairmount Funds Management LLC Director | Conversion | +41,130 | 41,140 | ||
| 2024-09-16 | Fairmount Funds Management LLC Director | Conversion | +252,890 | 294,020 | ||
| 2024-09-16 | Fairmount Funds Management LLC Director | Conversion | +709,794 | 1,003,814 |
Page 5 of 8 · 145 trades